TGF-β Antibodies
JP2025508073A5Pending Publication Date: 2026-03-13UNIVERSITE CATHOLIQUE DE LOUVAIN
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024553443
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-03-09
- Filing Date
- 2023-03-09
- Publication Date
- 2026-03-13
AI Technical Summary
Technical Problem
There is a need for antibodies that can bind and activate TGF-β1 to enhance immunosuppressive activity, particularly for treating autoimmune and alloimmune diseases, as well as for enhancing tumor-inhibitory activity.
Method used
Development of antibodies or antigen-binding fragments that specifically bind to latent TGF-β1, activating it by releasing mature TGF-β1 from the inhibition caused by the LAP region, thereby increasing its immunosuppressive activity.
Benefits of technology
The antibodies effectively activate TGF-β1, enhancing its immunosuppressive effects, which can be therapeutic in autoimmune and alloimmune diseases, as well as in conditions requiring tumor-inhibitory activity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to antibodies capable of activating TGF-β1, in particular antibodies capable of binding to latent TGF-β1 and liberating mature TGF-β1 cytokine, and uses thereof.
Need to check novelty before this filing date? Find Prior Art